Mercy BioAnalytics utilizes its proprietary Mercy Halo™ platform, which employs low-cost qPCR technology to detect cancer-associated biomarkers on extracellular vesicles in blood samples. This approach addresses the challenge of late cancer diagnoses by providing highly sensitive and specific tests for early-stage cancer detection, improving treatment options and patient outcomes.
Funding
$68.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NLFounders
Product
Problem
Current cancer testing methods often prove inadequate or inaccessible, leading to late diagnoses and limited treatment options. Early-stage cancer detection remains a significant challenge due to the limitations of existing technologies. Detecting cancer at its earliest stages, when it's most curable, is critical for improving patient outcomes.
Solution
Mercy BioAnalytics addresses the challenge of early cancer detection with the Mercy Halo™ platform, a technology that utilizes low-cost qPCR to detect cancer-associated biomarkers on extracellular vesicles (EVs) in blood samples. The platform identifies combinations of cancer-associated biomarkers on individual EVs, enabling the development of sensitive and specific blood-based tests. By focusing on EVs, which are more abundant than circulating DNA, the platform enhances the specificity of cancer detection. This approach aims to provide accessible and accurate tests for early-stage cancer detection, ultimately improving treatment options and patient outcomes.
Target Audience
The primary target audience includes healthcare providers and patients seeking early and accurate cancer detection methods to improve treatment outcomes.
Features
- Employs low-cost qPCR technology for biomarker detection.
- Focuses on extracellular vesicles (EVs) as a stable and abundant source of cancer-associated biomarkers.
- Identifies co-localized biomarkers on individual EVs to enhance test specificity.
- Aims to detect cancer at its earliest stages, improving chances of successful treatment.
- Developing blood-based tests that are broadly accessible.